WuXi AppTec

Last updated
WuXi AppTec
Company type Public
Industry Contract Research Organizations
Pharmaceutical
Biopharmaceutical
Medical Devices
Founded2000;25 years ago (2000)
Headquarters Shanghai, China
Key people
Ge Li
Website www.wuxiapptec.com OOjs UI icon edit-ltr-progressive.svg

WuXi AppTec (WuXi is pronounced as Wu-shee) is a contract research and manufacturing company in the global pharmaceutical industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America and Europe.

Contents

History

WuXi PharmaTech was founded in December 2000 in Shanghai by organic chemist Ge Li. [1] [2] The company initially focused on chemistry services. [3] [4]

In 2007, the company launched an initial public offering in the U.S. with shares traded on the New York Stock Exchange under the symbol "WX." [5] That year, it also opened chemistry facilities in Tianjin. [6]

In 2008, WuXi PharmaTech acquired AppTec Laboratory Services Inc., a US-based company founded in 2001 with expertise in medical-device and biologics testing and with facilities in St. Paul, MN; Philadelphia, PA; and Atlanta, GA. In the same year the company was renamed WuXi AppTec. [7] [8] WuXi AppTec opened a toxicology facility in Suzhou in 2009. [9]

WuXi AppTec's subsidiary, WuXi STA, opened a large-scale manufacturing facility in Jinshan in 2010. The company began a biologics discovery, development, and manufacturing operation in Shanghai and Wuxi City in 2011. At the same year, WuXi AppTec acquired MedKey, a China-based clinical research company, [10] and Abgent, a San Diego company and one of the world's largest manufacturers of antibodies for biological research and drug discovery. [11] In 2012, WuXi AppTec opened a chemistry facility in Wuhan and a GMP biologics drug-substance facility in Wuxi City. That year WuXi AppTec also entered into a joint venture with MedImmune, the biologics arm of AstraZeneca, to co-develop MEDI5117, an anti-IL6 antibody for rheumatoid arthritis for the Chinese market. [12] In 2013, WuXi AppTec formed a joint venture with the global clinical contract research organization PRA International (now called PRA Health Sciences) to build a clinical research business in China. [13]

In 2014, WuXi AppTec opened a new biologics biosafety testing facility in Suzhou. In the same year, WuXi AppTec acquired XenoBiotic Laboratories, Inc. (XBL), a contract research organization with 27 years of operation that provides bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries. [14]

In 2015, WuXi AppTec and other Chinese firms delisted their stocks from U.S. exchanges in a bid to obtain higher valuations closer to home. [15] WuXi AppTec completed its merger with WuXi Merger Limited, a wholly owned subsidiary of New WuXi Life Science Limited. As a result of the merger, New WuXi Life Science Limited acquired the company in a cash transaction valued at approximately US$3.3 billion. [16] In 2016, WuXi STA opened a new campus in Changzhou [17] and operations in San Diego. In the same year, WuXi AppTec acquired Crelux GmbH, a structure-based drug discovery provider based in Munich, Germany. [18] In 2017, WuXi AppTec acquired HD Biosciences (HDB), a biology focused preclinical drug discovery contract research organization (CRO). [19]

In 2015, the company launched the subsidiary WuXi NextCODE following the acquisition of NextCODE Health, a bioinformatics startup company which emerged from the Icelandic firm deCODE genetics in 2013. [20] Later, in 2019, WuXi NextCODE separated from WuXi AppTec in response to new regulations in China, and became Genuity Science. This company was then acquired by the New York biotech firm HiberCell in August 2021. [21]

In 2017, WuXi AppTec's biologics division, WuXi Biologics, was spun off and listed on the Hong Kong Stock Exchange. [22] In 2018, WuXi AppTec itself completed an initial public offering in Shanghai, raising over $900 million, and then subsequently listed shares in Hong Kong for an initial valuation of $1 billion. [23] [24]

In 2019, WuXi AppTec acquired Pharmapace, a U.S.-based biometrics and clinical data company. [25]

In 2020, WuXi STA opened a new oligonucleotide API plant in Changzhou. [26] The next year, the subsidiary acquired a tablet and capsule manufacturing plant in Switzerland from Bristol Myers Squibb. [27]

In 2021, WuXi AppTec acquired Oxgene, a UK-based cell and gene therapy firm. [28] In 2022, the firm announced plans to develop a manufacturing site in Middletown, Delaware, as well as a $1.4 billion facility expansion in Singapore. [29] [30] The company also opened. a high-potency API facility in Jiangsu, China. [31]

In January 2024, WuXi AppTec's share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. [32] [33] [34] The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army (PLA) as a part of the Chinese Communist Party (CCP)'s military-civil fusion strategy. [35] Members of the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party subsequently called for sanctions against WuXi AppTec. [36] WuXi AppTec denied any affiliation with the CCP and PLA and launched a lobbying campaign in the US in response. [37] According to the Federal Bureau of Investigation, United States Department of State, and Director of National Intelligence, WuXi AppTec transferred US intellectual property to the PLA without consent. [38]

In October 2024, WuXi AppTec was reportedly considering selling its facilities in the U.S. and Europe due to the Biosecure Act, which has been discouraging potential clients. [39] In December 2024, WuXi AppTec announced that it would sell its Oxford Genetics and WuXi Advanced Therapies to a U.S.-based private equity firm. [40] In January 2025, the company divested its U.S. medical device testing operations, with locations in Minnesota and Georgia, to the medical device contract research organization NAMSA. [41]

Operations

WuXi AppTec provides a range of services, including drug discovery, development, and manufacturing for small molecules, biologics, peptides and more. [3] [42] As of 2025, the company reported around 39,000 employees and 6,000 customers. [43] WuXi Apptec's global network includes 20 sites, with major hubs in China, the United States, Germany, Switzerland, and Singapore. [44] [43] Clients have included Chinese drugmakers like Jiangsu Hengrui, along with American and European firms like GlaxoSmithKline, AstraZeneca and Pfizer. [45]

WuXi Apptec is listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange, and is a component of the Hang Seng Index. [46] [47] [48]

References

  1. "Company Profile/ leadership". WuXi AppTec. Archived from the original on 15 April 2021. Retrieved 29 March 2021.
  2. "Company Profile/ History". WuXi AppTec. Archived from the original on 15 April 2021. Retrieved 29 March 2021.
  3. 1 2 Tremblay, Jean-François; C, special to; EN (2025-01-21). "WuXi AppTec is C&EN's 2018 Company of the Year". Chemical & Engineering News. Retrieved 2025-09-05.
  4. Dyer, Geoff (October 18, 2005). "China: Seeds are sown but few are harvested". The Financial Times. Retrieved September 4, 2025.
  5. "Form 424(b)(4)". www.sec.gov. Retrieved 2025-09-05.
  6. "Wuxi chemistry lab opens in Tianjin". Chemical & Engineering News. 2025-01-21. Retrieved 2025-09-05.
  7. "Our History". WuXi AppTec. Archived from the original on 22 December 2023. Retrieved 26 December 2023.
  8. Nagaraj, Amulya; Shen, Samuel (4 January 2008). "WuXi to acquire U.S.-based biopharmaceutical company". reuters.com. Archived from the original on 7 December 2023. Retrieved 3 January 2024.
  9. "Our History". WuXi AppTec. 29 March 2019. Archived from the original on 17 June 2020. Retrieved 24 June 2020.
  10. WuXi Acquires Chinese Clinical CROs MedKey and Jiecheng Archived 2022-06-26 at the Wayback Machine 24 October 2011 www.genengnews.com, accessed 28 March 2021
  11. WuXi PharmaTech Acquires Abgent, a Leading Producer of Biological Research Reagents Archived 2024-03-20 at the Wayback Machine 14 October 2011 www.fiercebiotech.com, accessed 28 March 2021
  12. MedImmune, WuXi form joint venture Archived 2024-03-20 at the Wayback Machine 10 September 2012 www.biospectrumasia.com, accessed 28 March 2021
  13. WuXi and PRA form Chinese joint venture Archived 2021-01-11 at the Wayback Machine 8 January 2013 www.pmlive.com, accessed 28 March 2021
  14. WuXi PharmaTech acquires XenoBiotic Labs Archived 2015-10-24 at the Wayback Machine 1 October 2014 www.thepharmaletter.com, accessed 28 March 2021
  15. Lane, E. J. (2015-08-17). "Going private for WuXi PharmaTech opens dealmaking options | Fierce Pharma". www.fiercepharma.com. Retrieved 2025-09-05.
  16. Conyers advises New WuXi Life Science Ltd. in connection with US$3.3 billion buyout Archived 2021-04-14 at the Wayback Machine www.conyers.com, accessed 29 March 2021
  17. WuXi AppTec's STA Subsidiary Opens New Campus In Changzhou Archived 2022-11-13 at the Wayback Machine 4 March 2016 www.biospace.com, accessed 29 March 2021
  18. WuXi Apptec acquire Crelux GmbH Archived 2024-03-20 at the Wayback Machine 19 April 2016 biopharma-asia.com, accessed 29 March 2021
  19. WuXi AppTec acquires HD Biosciences Archived 2021-01-22 at the Wayback Machine 20 January 2017 www.centerwatch.com, accessed 29 March 2021
  20. Fidler, Ben (23 October 2013). "DeCode Spinout, NextCode Health, Launches With $15M From Arch, Polaris". Xconomy. Boston. Archived from the original on 27 June 2020. Retrieved 24 June 2020.
  21. Vinluan, Frank (2021-08-16). "HiberCell's Genuity buyout brings $100M, plus alliances with Ionis and AbbVie". MedCity News. Retrieved 2025-09-08.
  22. "WuXi Biologics prices HK IPO at top as investors seek growth business". Reuters. 2017-06-06. Retrieved 2025-09-08.
  23. Liu, Angus (2018-03-28). "WuXi AppTec gets fast-track approval for $900M-plus Shanghai IPO | Fierce Biotech". www.fiercebiotech.com. Retrieved 2025-09-08.
  24. Chiu, Joanne (2018-11-28). "Chinese Drug Researcher Kicks Off $1 Billion Hong Kong Listing". Wall Street Journal. ISSN   0099-9660 . Retrieved 2025-09-08.
  25. Adams, Ben (2019-05-08). "China's WuXi AppTec buys up U.S. Pharmapace, boosting biometrics offering | Fierce Biotech". www.fiercebiotech.com. Retrieved 2025-09-09.
  26. Mullin, Rick (2025-01-21). "WuXi's STA unit opens oligonucleotide plant". Chemical & Engineering News. Retrieved 2025-09-09.
  27. Kansteiner, Fraiser (2021-02-02). "Bristol Myers offloading Swiss tablet and capsule plant to Chinese CDMO WuXi STA | Fierce Pharma". www.fiercepharma.com. Retrieved 2025-09-09.
  28. Hargreaves, Ben (March 4, 2021). "WuXi AppTec absorbs Oxgene to expand cell and gene services". BioProcess International. Retrieved September 9, 2025.
  29. Kostelni, Natalie (June 28, 2021). "Delaware signs off on $19M in tax incentives for WuXi AppTec division's Project Dragonfly". www.bizjournals.com. Retrieved 2025-09-09.
  30. "Chinese Biotech Duo Eyes $2.8 Billion Singapore Expansion - Caixin Global". www.caixinglobal.com. Retrieved 2025-09-09.
  31. Keenan, Joseph (2022-06-28). "WuXi debuts another high-potency API production facility". www.fiercepharma.com. Retrieved 2025-09-09.
  32. "WuXi Bio Denies Military Ties After Shares Slumped on US Bill". Bloomberg News . 2024-01-29. Archived from the original on 2024-01-29. Retrieved 2024-01-30.
  33. "WuXi AppTec Shares Continue Slide After Company Calls U.S. Draft Bill Findings Inaccurate" . The Wall Street Journal . January 28, 2024. Archived from the original on January 29, 2024. Retrieved January 29, 2024.
  34. "WuXi Company Shares Tumble on U.S. Bill Aimed at Chinese Biotech" . The Wall Street Journal . February 2, 2024. Archived from the original on February 1, 2024. Retrieved February 2, 2024.
  35. Cheung, Sunny; Hope, Arran; Mattis, Peter (February 9, 2024). "Red Genes: Assessing WuXi AppTec's Ties to the Party-Army-State in China". Jamestown Foundation . Archived from the original on 2024-02-10. Retrieved 2024-02-11.
  36. Martina, Michael (February 12, 2024). "US lawmakers call for sanctions on China's WuXi AppTec biotech firm". Reuters . Retrieved February 12, 2024.
  37. "Chinese pharma group lobbies against US biotech crackdown" . Financial Times . Archived from the original on 2024-03-19. Retrieved 2024-03-20.
  38. "China's WuXi AppTec shared US client's data with Beijing, US intelligence officials told senators". Reuters . March 28, 2024. Retrieved March 28, 2024.
  39. Barnes, Oliver; Fontanella-Khan, James; Olcott, Eleanor (October 3, 2024). "China's WuXi explores sale of pharma units as US restrictions loom". Financial Times . Retrieved December 25, 2024.
  40. "China's WuXi to sell Advanced Therapies unit amid US restrictions". Reuters . December 24, 2024. Retrieved December 25, 2024.
  41. "WuXi AppTec sees growth after 2024 dip, plans 'lean' operations to temper 'external opportunities'". Endpoints News. Retrieved 2025-09-04.
  42. Haigney, Susan (2024-01-09). "WuXi AppTec Expands Peptide and API Manufacturing". BioPharm International. Retrieved 2025-09-12.
  43. 1 2 "2024 Annual Report" (PDF). Wuxiapptec.com. Retrieved September 11, 2025.
  44. Slabodkin, Greg (2025-08-18). "Q&A: WuXi AppTec's key investment focus is on expanding capabilities for new modalities". Pharma Manufacturing. Retrieved 2025-09-13.
  45. Dreyer, Jacob (2025-08-17). "China's Biotech Is Cheaper and Faster" . Retrieved 2025-09-12.
  46. "603259.SS - | Stock Price & Latest News | Reuters". www.reuters.com. Retrieved 2025-09-12.
  47. "WuXi AppTec Co., LTD (2359.HK)". Yahoo! Finance. Retrieved September 12, 2025.
  48. "HSI Members - Hong Kong Hang Seng Index". Bloomberg.com. Archived from the original on 2017-07-05. Retrieved 2025-09-12.